Coronary/Structural Heart

Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update

Coronary/Structural Heart by 0 comments

DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA Ii with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US INDii filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in validated clinical measures Heart failure disease-modifying profile – safe, rapid and effective decongestion with no congestion-related heart failure re-hospitalizations observed […]

Continue Reading →

Prevencio Announces Agreement with Alivio Health Expanding Access to AI-Driven Cardiac HART Tests Offered by Atlas Genomics

Coronary/Structural Heart by 0 comments

Expanded Access for 125,000 American Lives for Highly Accurate, Novel Blood Tests KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc. today announces that Atlas Genomics, Prevencio’s performing laboratory for its Artificial Intelligence (AI)-driven cardiac HART blood tests, has entered into a preferred provider agreement with Alivio Health to provide expanded access for Prevencio’s HART tests. The coverage includes […]

Continue Reading →

US Heart & Vascular and Willowbrook Cardiovascular Associates Announce Partnership to Deliver Quality Cardiovascular Care to the Houston Market

Coronary/Structural Heart by 0 comments

Partnership Reinforces USHV’s Strong Position in Houston and Supports Long-Term Goals for National Footprint Expansion NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), the leading national provider of support services to cardiovascular physician practices, announced today that it has signed a definitive agreement regarding its partnership with Willowbrook Cardiovascular Associates (“Willowbrook”), […]

Continue Reading →

Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 inhibitor in Heart Failure

Coronary/Structural Heart by 0 comments

CARDINAL-HF is the first Phase 2 proof-of-concept trial of a PDE9 inhibitor in heart failure Large-scale trial builds upon encouraging data generated in Cardurion’s Phase 1b trial CARDINAL-HF will examine the effects of CRD-740, Cardurion’s PDE9 inhibitor, in both types of heart failure and in key subsets of these patients […]

Continue Reading →

Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial

Coronary/Structural Heart Regulatory by 0 comments

SHANGHAI, July 15, 2022 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized device pioneer in the treatment for cardiopulmonary diseases, today announced that it has successfully concluded the first Pre-Sub meeting with the U.S. Food and Drug Administration (“FDA”) for its Pulmonary Artery Denervation (PADN) Global Trial. Dr. Shaoliang Chen, Chair of Pulnovo […]

Continue Reading →

PIH Health Good Samaritan Hospital First in LA to Use Next-Generation Evolut™ FX TAVR System

Coronary/Structural Heart by 0 comments

Evolut FX TAVR System Used to Treat Patient with Symptomatic Severe Aortic Stenosis LOS ANGELES, July 13, 2022 /PRNewswire/ — PIH Health Good Samaritan Hospital is the first hospital in Los Angeles to treat patients with the next-generation, self-expanding Evolut FX Transcatheter Aortic Valve Replacement (TAVR) System, a minimally invasive alternative to open-heart surgical aortic […]

Continue Reading →

SoniVie Announces successful procedure with TIVUS system on first patient enrolled for REDUCED1 Pilot study

Coronary/Structural Heart by 0 comments

TEL AVIV, Israel, July 13, 2022 /PRNewswire/ — SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS™) System to treat a variety of hypertensive disorders, announced that on May 30th 2022 the first patient was treated with its Renal Artery Denervation TIVUS™ technology, as part of the recently FDA IDE-approved Pilot […]

Continue Reading →

Intratech Medical enrolls patients to first ever human study for treatment of accute heart attacks using Booster™ – coronary sinus spiral balloon therapy

Coronary/Structural Heart by 0 comments

TEL AVIV, Israel, July 13, 2022 /PRNewswire/ — Intratech Medical, developer of the Booster™ spiral balloon therapy for the treatment of AMI patients, announced the successful enrollment of two patients in a multi-center first in human study to assess the safety and technical performance of their Booster balloon in the treatment of patients […]

Continue Reading →

Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab

Coronary/Structural Heart by 0 comments

Additional Pharmacodynamic Data on Abelacimab Released at the 2022 Congress of the International Society on Thrombosis and Haemostasis (ISTH) CAMBRIDGE, Mass., July 13, 2022 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the […]

Continue Reading →

Filling gap in market: VenusP-Valve™ approved by China’s NMPA

Coronary/Structural Heart by 0 comments

HANGZHOU, China, July 13, 2022 /PRNewswire/ — On July 11, 2022, VenusP-ValveTM, Venus Medtech’s in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, was approved by China’s National Medical Products Administration (NMPA) for the treatment of severe pulmonary regurgitation (≥3+) in patients after congenital heart defects (CHD) procedure with native right ventricular outflow tract (RVOT). […]

Continue Reading →
1 … 166 167 168 169 170 … 422